Post-Clearance: Your AI’s Real Regulatory Test Begins Now
Getting FDA clearance for an AI health tool is a major achievement, but it’s the starting gun, not the finish line. For any imaging and…
Getting FDA clearance for an AI health tool is a major achievement, but it’s the starting gun, not the finish line. For any imaging and…
The field for AI health tools shifted deeply with the FDA’s 2021 AI/ML Action Plan. This document did not merely outline a vision for adaptive…
Getting FDA clearance for an AI health tool proves it’s a safe and effective medical device, but that’s only half the battle. That clearance does…
The proliferation of AI-powered health tools has introduced a new layer of complexity for health plans, particularly in assessing vendor compliance. A significant and often…
Companies developing AI health tools without a clear FDA Software as a Medical Device (SaMD) pathway face increasing enforcement actions and exclusion from health plan…
For AI health tools, you have to be able to tell real performance evidence apart from marketing collateral. It’s not just an academic exercise for…
What clinicians and procurement teams need to get is that an FDA AI device designation isn’t a verdict on the product itself. It’s a signal…
Whether an AI health tool faces a slap on the wrist or a major regulatory headache comes down to one thing: is its post-market surveillance…
The regulatory world for adaptive AI in health isn’t a theoretical problem anymore. It’s a structured pathway, built out by the FDA’s recent, targeted work.…
A lot of companies assume that getting an FDA clearance for their AI-driven health tool means the European market is a shoo-in. They’re wrong. The…